Community partnerships lead to more inclusive health care for neurodiverse individuals

A new paper shows how partnering with the community can lead to more inclusive health care, especially for individuals with autism and other neurodevelopmental disabilities.

FS-102 by F-star Therapeutics for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

FS-102 is under clinical development by F-star Therapeutics and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction.

February 9, 2024

BMS’ confirmatory trial of Krazati hits primary endpoint following 2022 accelerated approval

Bristol Myers Squibb scored a confirmatory trial win for Krazati, the KRAS inhibitor it picked up earlier this year through its $4.8 billion acquisition of

April 2, 2024

AI and rural health care: A paradigm shift in America’s heartland

The use of artificial intelligence is happening in “unlikely places.” So says a recent working paper published by the National Bureau of Economic Research. While much

June 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.